机构:
Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USAUniv Maryland, Dept Neurol, Baltimore, MD 21201 USA
Lee, Hyoung-Gon
[3
]
Zhu Xiongwei
论文数: 0引用数: 0
h-index: 0
机构:
Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USAUniv Maryland, Dept Neurol, Baltimore, MD 21201 USA
Zhu Xiongwei
[3
]
Perry, George
论文数: 0引用数: 0
h-index: 0
机构:
Univ Texas San Antonio, Coll Sci, San Antonio, TX USA
Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USAUniv Maryland, Dept Neurol, Baltimore, MD 21201 USA
Perry, George
[2
,3
]
Smith, Mark A.
论文数: 0引用数: 0
h-index: 0
机构:
Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USAUniv Maryland, Dept Neurol, Baltimore, MD 21201 USA
Smith, Mark A.
[3
]
Castellani, Rudy J.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Maryland, Div Neuropathol, Dept Pathol, Baltimore, MD 21201 USAUniv Maryland, Dept Neurol, Baltimore, MD 21201 USA
Castellani, Rudy J.
[4
]
机构:
[1] Univ Maryland, Dept Neurol, Baltimore, MD 21201 USA
[2] Univ Texas San Antonio, Coll Sci, San Antonio, TX USA
[3] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA
[4] Univ Maryland, Div Neuropathol, Dept Pathol, Baltimore, MD 21201 USA
The management of Alzheimer's disease (AD) has been a long-standing challenge and area of interest. Advances in knowledge of the pathogenesis of disease and an increase in disease burden have prompted investigation into innovative therapeutics over the last two decades. This article reviews the various treatments of AD including those targeted towards cholinergic deficiency, oxidative stress, the amyloid cascade, inflammation, and excitotoxicity. Second generation cholinesterase inhibitors remain the preferred therapy for early and intermediate AD while the glutamate antagonist, memantine, is also approved for advanced stages of disease. Antioxidants may delay disease progression, while data on other experimental therapies remain equivocal at best. Gene therapy directed at neurotropins is currently under investigation with some intriguing preliminary results; however, the number of patients examined is too few to be conclusive. Drugs directly targeting amyloid-beta, particularly the amyloid-beta vaccine, continue to be investigated and their forthcoming results are eagerly anticipated. (c) 2008 Elsevier Masson SAS. All rights reserved.